AKT2 siRNA (Rat)
Cat# MBS827144-15nmol
Size : 15nmol
Brand : MyBiosource
Contact local distributor :
Phone : +1 850 650 7790
AKT2 siRNA – RAC-Beta Serine/Threonine-Protein Kinase (Rat)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS827144MBS827144 is an siRNA targeting AKT2. Also known as AKT2 siRNA (Rat). Reactive in Rat. Host: Synthetic. siRNA to inhibit AKT2 expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
AKT2, siRNA
Full Product Name
AKT2 siRNA (Rat)
Product Gene Name
AKT2 sirna
Product Synonym Names
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
Host
Synthetic
Species Reactivity
Rat
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
AKT2 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
55,543 Da
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat AKT2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for AKT2 sirna
RNA Interference (RNAi)
Other Notes
Small volumes of AKT2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for AKT2. It may not necessarily be applicable to this product.
NCBI Official Full Name
RAC-beta serine/threonine-protein kinase
NCBI Official Synonym Full Names
v-akt murine thymoma viral oncogene homolog 2
NCBI Official Symbol
Akt2
UniProt Protein Name
RAC-beta serine/threonine-protein kinase
UniProt Synonym Protein Names
Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
Protein Family
Potassium channel
UniProt Gene Name
Akt2
UniProt Synonym Gene Names
PKB beta
UniProt Entry Name
AKT2_RAT
NCBI Protein Information
RAC-beta serine/threonine-protein kinase
NCBI Summary for AKT2
may be involved in phosphatidylinositol 3-kinase (PI3-K) mediated signaling [RGD, Feb 2006]
UniProt Comments for AKT2
Akt2: an AGC kinase. Plays critical roles in glucose metabolism and the development or maintenance of proper adipose tissue and islet mass for which other Akt/PKB isoforms are unable to fully compensate. Amplified and overexpressed in human ovarian carcinoma cell lines and amplified in some primary ovarian and pancreatic tumors. Antisense blocks invasiveness in xenografts. Expressed in several insulin-responsive tissues, and one case of Type II diabetes has been associated with a likely LOF point mutation. Mouse mutants have defects in insulin response.
Protein type: Protein kinase, Ser/Thr (non-receptor); Kinase, protein; Oncoprotein; EC 2.7.11.1; Protein kinase, AGC; AGC group; AKT family
Cellular Component: nucleoplasm; intracellular membrane-bound organelle; plasma membrane; cell cortex; nucleus; cytosol; vesicle
Molecular Function: protein serine/threonine kinase activity; protein binding; protein kinase C binding; ATP binding; protein kinase activity
Biological Process: response to muscle activity; positive regulation of positive chemotaxis; positive regulation of nitric oxide biosynthetic process; multicellular organismal development; positive regulation of glycogen biosynthetic process; intracellular protein transport across a membrane; positive regulation of vesicle fusion; negative regulation of caspase activity; protein amino acid phosphorylation; response to insulin stimulus; regulation of translation; positive regulation of glucose import; negative regulation of RNA splicing; protein kinase B signaling cascade; response to nutrient levels; glycogen biosynthetic process; positive regulation of signal transduction; carbohydrate transport; myelin maintenance in the peripheral nervous system; glucose metabolic process; response to osmotic stress; positive regulation of peptidyl-serine phosphorylation; cellular response to hormone stimulus; positive regulation of fatty acid beta-oxidation; cellular response to insulin stimulus; insulin receptor signaling pathway; positive regulation of transcription from RNA polymerase II promoter; positive regulation of protein amino acid phosphorylation; positive regulation of cell migration; negative regulation of apoptosis
Show more Protein type: Protein kinase, Ser/Thr (non-receptor); Kinase, protein; Oncoprotein; EC 2.7.11.1; Protein kinase, AGC; AGC group; AKT family
Cellular Component: nucleoplasm; intracellular membrane-bound organelle; plasma membrane; cell cortex; nucleus; cytosol; vesicle
Molecular Function: protein serine/threonine kinase activity; protein binding; protein kinase C binding; ATP binding; protein kinase activity
Biological Process: response to muscle activity; positive regulation of positive chemotaxis; positive regulation of nitric oxide biosynthetic process; multicellular organismal development; positive regulation of glycogen biosynthetic process; intracellular protein transport across a membrane; positive regulation of vesicle fusion; negative regulation of caspase activity; protein amino acid phosphorylation; response to insulin stimulus; regulation of translation; positive regulation of glucose import; negative regulation of RNA splicing; protein kinase B signaling cascade; response to nutrient levels; glycogen biosynthetic process; positive regulation of signal transduction; carbohydrate transport; myelin maintenance in the peripheral nervous system; glucose metabolic process; response to osmotic stress; positive regulation of peptidyl-serine phosphorylation; cellular response to hormone stimulus; positive regulation of fatty acid beta-oxidation; cellular response to insulin stimulus; insulin receptor signaling pathway; positive regulation of transcription from RNA polymerase II promoter; positive regulation of protein amino acid phosphorylation; positive regulation of cell migration; negative regulation of apoptosis
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with AKT2 sirna
| Reference Product | PubMed Publications |
|---|---|
| Pten sirna | >102 publications with AKT2 and Pten |
| Mtor sirna | >100 publications with AKT2 and Mtor |
| Foxo1 sirna | >32 publications with AKT2 and Foxo1 |
| Pdpk1 sirna | >13 publications with AKT2 and Pdpk1 |
| Foxo3 sirna | >12 publications with AKT2 and Foxo3 |
| Tsc2 sirna | >7 publications with AKT2 and Tsc2 |
| Phlpp1 sirna | >7 publications with AKT2 and Phlpp1 |
| Ilk sirna | >4 publications with AKT2 and Ilk |
| Tsc1 sirna | >2 publications with AKT2 and Tsc1 |
Pathways associated with AKT2 sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| AMPK Signaling Pathway antibodies | AMPK Signaling Pathway Diagram |
| AMPK Signaling Pathway antibodies | AMPK Signaling Pathway Diagram |
| Activation Of AKT2 Pathway antibodies | Activation Of AKT2 Pathway Diagram |
| Acute Myeloid Leukemia Pathway antibodies | Acute Myeloid Leukemia Pathway Diagram |
| Acute Myeloid Leukemia Pathway antibodies | Acute Myeloid Leukemia Pathway Diagram |
| Adaptive Immune System Pathway antibodies | Adaptive Immune System Pathway Diagram |
| Adipocytokine Signaling Pathway antibodies | Adipocytokine Signaling Pathway Diagram |
| Adipocytokine Signaling Pathway antibodies | Adipocytokine Signaling Pathway Diagram |
| Adrenergic Signaling In Cardiomyocytes Pathway antibodies | Adrenergic Signaling In Cardiomyocytes Pathway Diagram |
| Adrenergic Signaling In Cardiomyocytes Pathway antibodies | Adrenergic Signaling In Cardiomyocytes Pathway Diagram |
Diseases associated with AKT2 sirna
| Disease Name | Pubmed Publications |
|---|---|
| Breast Neoplasms Antibodies | >85 publications with AKT2 and Breast Neoplasms |
| Ovarian Neoplasms Antibodies | >69 publications with AKT2 and Ovarian Neoplasms |
| Lung Diseases Antibodies | >49 publications with AKT2 and Lung Diseases |
| Lung Neoplasms Antibodies | >48 publications with AKT2 and Lung Neoplasms |
| Liver Diseases Antibodies | >43 publications with AKT2 and Liver Diseases |
| Cardiovascular Diseases Antibodies | >37 publications with AKT2 and Cardiovascular Diseases |
| Neoplasms, Experimental Antibodies | >37 publications with AKT2 and Neoplasms, Experimental |
| Nervous System Diseases Antibodies | >36 publications with AKT2 and Nervous System Diseases |
| Liver Neoplasms Antibodies | >31 publications with AKT2 and Liver Neoplasms |
| Brain Diseases Antibodies | >30 publications with AKT2 and Brain Diseases |
Organs/Tissues associated with AKT2 sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Liver Antibodies | >104 publications with AKT2 and Liver |
| Lung Antibodies | >70 publications with AKT2 and Lung |
| Brain Antibodies | >50 publications with AKT2 and Brain |
| Heart Antibodies | >49 publications with AKT2 and Heart |
| Connective Tissue Antibodies | >31 publications with AKT2 and Connective Tissue |
| Embryonic Tissue Antibodies | >29 publications with AKT2 and Embryonic Tissue |
| Prostate Antibodies | >29 publications with AKT2 and Prostate |
| Pancreas Antibodies | >27 publications with AKT2 and Pancreas |
| Kidney Antibodies | >24 publications with AKT2 and Kidney |
| Colon Antibodies | >19 publications with AKT2 and Colon |